AbbVie accused of hiding painful lump risk from Juvederm patients in new lawsuit

Licensed pharmacist Christina Garcia from Vacaville, California, filed a class action lawsuit against AbbVie on June 27, 2026, in the U.S. District Court for the Northern District of Illinois. The suit alleges the company's Juvederm dermal fillers cause disfiguring facial growths and that AbbVie's warning label does not disclose the specific risk.

The class action lawsuit's claims

Garcia claims she received several Juvederm injections in 2023 and paid thousands of dollars out of pocket per session. Juvaderm is an injectable gel used to restore facial contours and improve signs of aging, according to the drug's website. Garcia says she developed severe delayed-onset granulomas three years later, requiring hospital visits and multiple medical procedures.

Granulomas form when immune cells cluster around an infection or foreign object in the body. The class action lawsuit states facial symptoms can include hard lumps, swollen lymph nodes, vision problems and potentially permanent disfigurement and that the reaction can surface months or years after injection.

The complaint asserts that AbbVie has known about the risk of nodules at injection sites for more than 15 years and does not mention the word "granuloma" anywhere on Juvederm's labels, website glossary or patient safety materials. The label instead references nodules and describes them as minor side effects that resolve within a month, a characterization the lawsuit claims is misleading because dermal-filler nodules can persist and worsen far beyond that window.

Why the risk matters

Juvederm belongs to a family of hyaluronic acid fillers, and patients in the United States received more than 5 million HA filler injections in 2023 alone. The complaint cites research by Dr. David K. Funt documenting delayed-onset nodule rates of 0.5% to 0.98% for Juvederm, which is higher than rates for other HA fillers.

The class action also highlights butanediol diglycidyl ether, a crosslinking agent used to stabilize Juvederm's HA. Scientific literature cited in the complaint describes the combination of BDDE and HA as proinflammatory and hypothesizes it triggers delayed granuloma formation. The lawsuit notes Juvederm's warning label never mentions BDDE, referring instead only to a "physiologic buffer."

AbbVie's own Food and Drug Administration premarket study of 72 subjects reportedly found that 65% to 68% of participants developed lumps and bumps at injection sites with nodule rates between 11% and 22% depending on the product variant.

The legal claims

The complaint brings five claims against AbbVie:

  • California Unfair Competition Law, which bars unlawful, unfair and fraudulent business practices
  • California Consumer Legal Remedies Act, which lets consumers sue over deceptive sales practices
  • Strict liability failure to warn, which holds manufacturers responsible for injuries from defective products regardless of intent
  • Negligent failure to warn, which requires proof the company did not act with reasonable care in communicating risks
  • Unjust enrichment, which is a claim that a company profited unfairly at consumers' expense

What the case means for Juvederm patients

Garcia asked the court to certify the class, award damages, force AbbVie to give up profits and order the company to revise Juvederm's labeling. The proposed class action seeks to represent U.S. and California Juvederm purchaserswith subclasses for those who developed granulomas.

For now, there is no settlement, no claims process and no money to collect. AbbVie has not publicly responded, and no court has certified a class. The allegations remain unproven.